Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for BMS in the
ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark BMS' s performance against key rivals in the ethical
pharmaceutical sector
- See how the recently launched Atripla and Orencia will drive BMS' s growth
to 2012
- Evaluate the prospects of BMS' s leading thrombosis treatment Plavix, which
will come under pressure from new competition and lose patent protection
View Cart
